financetom
Business
financetom
/
Business
/
Qiagen Q3 Adjusted Earnings, Revenue Increase; Raises 2024 Adjusted Earnings Guidance
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Qiagen Q3 Adjusted Earnings, Revenue Increase; Raises 2024 Adjusted Earnings Guidance
Nov 9, 2024 11:55 AM

04:30 AM EST, 11/07/2024 (MT Newswires) -- Qiagen ( QGEN ) reported Q3 adjusted earnings late Wednesday of $0.57 per diluted share, up from $0.50 a year earlier.

Analysts polled by Capital IQ expected $0.55.

Revenue for the quarter was $501.9 million compared with $475.9 million a year earlier.

Analysts surveyed by Capital IQ expected $491.5 million.

The company said its 2024 adjusted diluted EPS outlook has been increased to at least $2.19 from $2.16 previously. Analysts polled by Capital IQ expect $2.19. The company reaffirmed its 2024 sales outlook of at least $1.99 billion. Analysts polled by Capital IQ expect $1.97 billion.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Cantor Equity Partners Closes $100 Million IPO
Cantor Equity Partners Closes $100 Million IPO
Aug 14, 2024
05:49 PM EDT, 08/14/2024 (MT Newswires) -- Cantor Equity Partners ( CEP ) said late Wednesday that it closed its initial public offering of 10 million Class A ordinary shares at $10 apiece. The company said its shares began trading Tuesday on the Nasdaq Global Market under the symbol CEP. ...
Profits at Chile's Copec up nearly five fold in second quarter
Profits at Chile's Copec up nearly five fold in second quarter
Aug 14, 2024
Aug 14 (Reuters) - Chilean industrial conglomerate Empresas Copec on Wednesday posted a second-quarter net profit of $288 million, up nearly five times compared to profits of $59 million in the same quarter last year. Copec's revenues during the April-to-June period grew 3% to total $7.1 billion. ...
Incyte, Syndax Pharmaceuticals Get FDA Approval for Graft-Versus-Host Treatment
Incyte, Syndax Pharmaceuticals Get FDA Approval for Graft-Versus-Host Treatment
Aug 14, 2024
05:59 PM EDT, 08/14/2024 (MT Newswires) -- Incyte ( INCY ) and Syndax Pharmaceuticals ( SNDX ) said late Wednesday that the US Food and Drug Administration has approved niktimvo to treat chronic graft-versus-host disease. The treatment is for patients who have endured failure of at least two prior lines of systemic therapy in adult and pediatric patients weighing at...
BRIEF-Redwire to acquire Hera Systems, lifts 2024 revenue forecast
BRIEF-Redwire to acquire Hera Systems, lifts 2024 revenue forecast
Aug 14, 2024
Aug 14 (Reuters) - Redwire Corp ( RDW ): * REDWIRE TO ACQUIRE SPACECRAFT DEVELOPER HERA SYSTEMS * REDWIRE CORP ( RDW ) - ADJUSTING 2024 GUIDANCE FROM $300 MILLION IN REVENUE TO $310 MILLION IN REVENUE. Source text for Eikon: Further company coverage: ...
Copyright 2023-2026 - www.financetom.com All Rights Reserved